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Background
The vast networks of neural projections in the brain are essential for appropriate connectivity, but how these axons are specified during neuronal
differentiation remains unclear. The regulatory mechanisms coordinating axon formation are only beginning to emerge despite the identification of
key signaling molecules [1, 2, 3]. The protein kinase Liver Kinase B1 (LKB1) is a requisite component of the transduction machinery controlling
axon specification both in vitro and in vivo [4, 5] . LKB1 catalytic activity is allosterically regulated by the related pseudokinases, STRAD (STe20
Related ADapter)-alpha and STRAD-beta (STRAD? and STRAD?) (Figure?1A, [6, 7]). While little is known about STRAD? function,
homozygous deletion within the human LYK5 (STRAD?) locus (see Additional file 1: Figure S3A) results in a syndromic condition known as
polyhydramnios, megalencephaly, and symptomatic epilepsy (PMSE) [8]. These patients have craniofacial dysmorphology, cognitive deficits, and
intractable infantile-onset epilepsy. Given the clear impact on human health and brain development, further insights into STRAD pseudokinases
are needed to clarify their contributions to nervous system development and disease.
Figure 1: STRAD splice forms are expressed in a tissue-specific manner. (A) Schematic of mouse STRAD? and STRAD? proteins indicating
percent similarity between the two proteins. (B) Schematic of phylogenetic tree based on the STRAD gene from Bilaterians using Cnidaria as the
outgroup with posterior probabilities indicating support for nodes (0?1, 1 being the strongest support) labeled on nodes of interest. The tree is
based on MrBayes phylogenetic analysis (see Additional file 1: Figure S1). (C) Quantitative real-time-PCR of STRAD? and STRAD? across
developmental time. (D) Reverse transcriptase-PCR (RT-PCR) of STRAD? indicates that multiple variants exist in distinct tissue types. In
particular, the largest species (arrowhead) appears to be specific to brain, skeletal muscle and testes. (E) RT-PCR products from enriched cultures
of the dominant CNS cell types. (STRAD?-1 isoform ? arrowhead; STRAD?-4 isoform - asterisk). Cort neurons ? cerebral cortex primary neurons;
Interneurons ? medial ganglionic eminence primary neurons, Astrocytes ? primary post-natal day 1 astrocytes, Oligo ? primary oligodendrocyte
cultures. (F) RT-PCR of STRAD? isoforms across developmental time in the cerebal cortex. CNS, central nervous system. [see PDF for image]
Additional file 1: Figure S1: MrBayes tree of STRAD in metazoans. Figure S2. Analysis of STRAD splicing in adult tissues and during cortical
development. Figure S3. STRAD gene structure and diagram of mutant and conditional alleles, protein expression, Punnett square analysis of
STRAD-null survival, and immunocytochemistry of polarity markers in cultured neurons from the STRAD-null cerebral cortex. Figure S4.
Analysis of LKB1 mRNA expression in the STRAD-null cortex and additional protein stability data. Figure S5. Subcellular localization of
epitope-tagged LKB1 and STRAD variants expressed in HEK293 cells. Table S1. Table of antibodies used in this study.
LKB1 and either STRAD paralog form a heterotrimeric complex with either mouse protein-25 paralog, MO25? or ?, proteins shown to stabilize
the LKB1: STRAD dyad by binding to both proteins [6, 9]. This activated heterotrimeric complex phosphorylates and activates multiple
downstream kinase cascades. LKB1 substrates include the AMPK-like superfamily of kinases that are implicated in a number of physiologic roles
including cell metabolism and polarity [10, 11, 12, 13]. Interestingly, several members of this family have been shown to regulate various aspects
of axon formation: SAD-A/B (also known as BRSK1/2) in the developing cerebral cortex [5, 14], AMPK-?1/?2 for axonal growth under metabolic
stress [15] and neuronal polarity [16] as well as NUAK1/2 regulation of axonal branching [17].
Developmentally, STRAD? is expressed throughout the developing cerebral cortex, while STRAD? is found predominantly in post-migratory
neurons of the cortical plate [5], suggesting that these proteins may serve distinct functions during cortical development. Many critical questions
remain unaddressed regarding the roles of STRAD pseudokinases during cortical development. Importantly, it is unclear whether STRAD? and
STRAD? are functionally redundant during neuronal development and what distinct roles they might serve. Here, we address these questions and
provide new insights into the molecular mechanisms of STRAD protein function during neuronal development.
Results
STRAD? is the most evolutionarily conserved STRAD homolog among metazoans
Significant biochemical characterization has been conducted using vertebrate STRADs but few studies have addressed their function in vivo using
genetic loss-of-function approaches. Conversely, a number of phenomenological studies, but few biochemical analyses, have been performed using
invertebrate STRADs [18, 19, 20, 21]. We conducted a phylogenetic analysis of the STRAD proteins to contextualize the relationship and
functional contributions of the vertebrate paralogs. We find that metazoan STRAD proteins exhibit a high level of structural and sequence
similarity within (Figure?1A) and between species (Figure?1B and see Additional file 1: Figure S1). Our analysis further suggests that a single
STRAD gene duplication event occurred sometime between the origin of, and the last common ancestor for, the vertebrate lineage (Figure?1B and
Additional file 1: Figure S1). The phylogenetic pattern further indicates that the vertebrate STRAD? is more similar to the single invertebrate
STRAD ortholog than is STRAD?. This primacy is paralleled in our loss of function studies and by previous studies demonstrating the profound
effects of STRAD? loss-of-function mutations in human patients [8] and by the early postnatal lethality we observe in STRAD?-null, but not
STRAD?-null, mice (see Additional file 1: Figure S3C, data not shown).
A developmentally-regulated, tissue-restricted form of STRAD? is expressed exclusively by neurons in the CNS
Quantitative assessment of STRAD mRNA indicates that STRAD? levels decrease slightly, while STRAD? levels increase throughout cortical
development (Figure?1C). Closer examination of this pattern reveals the relative contributions of STRAD? splice variants (Figure?1F). A number
of STRAD? isoforms result from differentially utilized exons near the translation initiation site in various adult mouse tissues (Figure?1D and see
Additional file 1: Figure S2A), some of which are observed in Western blots of rat tissue [22] (see Additional file 1: Figure S2A for
nomenclature). Despite the fact that multiple STRAD? splicing events have been described in human cell lines [23] the in vivo expression pattern
of STRAD mRNA isoforms in adult tissues and during brain development has remained unknown. We characterized the expression of the STRAD
variants relative to one another using reverse transcriptase PCR. Our amplicon analysis indicates that the largest STRAD? variant (STRAD?-1)
results from the use of an alternate splice donor site and the inclusion of exon IV (see Additional file 1: Figure S2A). STRAD?-1 appears
predominantly in the nervous system, and to a much lesser extent in skeletal muscle and testes (arrowhead Figure?1D). Within the CNS, it is
exclusive to neurons (Figure?1E) and is developmentally regulated (Figure?1F). We observe three additional splice variants previously seen and a
novel fourth isoform, STRAD?-7, a predicted protein in humans (GenPep EAW94290). STRAD?-4 generates a larger amplicon, yet smaller
predicted protein (Figure?1D, see Additional file 1: Figure S2A). This isoform has previously been reported in human tumor cell lines [23], and we
detect it in most tissues (Figure?1D-F), but it is essentially absent from neurons (Figure?1E, asterisk). Similarly, human cells lines exhibit splicing
in the exons encoding carboxyl regions of the protein [23], but we do not detect these splice forms in mouse tissues (see Additional file 1: Figure
S2B).
Previous characterization of STRAD? indicated broad expression in adult tissues and reported a splice form that lacks exon 8 (STRAD?-2),
however insufficient resolution limited prior tissue expression studies of this isoform [24, 25]. Our results detect STRAD?-1 in all tissues probed
and STRAD?-2 is seen in all except skeletal and cardiac muscle (see Additional file 1: Figure S2C,D). Unlike STRAD?, transcriptional levels and
splicing of STRAD? appear to vary less in cortical tissue and neurons across developmental time in vivo and in vitro (see Additional file 1: Figure
S2E,F).
STRAD? splice forms and full-length STRAD? exhibit similar competence to drive axon formation
We addressed the functional significance of each STRAD? and STRAD? splice form in neurons using an ex utero electroporation gain-of-
function approach (Figure?2). We and others have previously shown the ubiquitous STRAD?-2 to be capable of driving the formation of multiple
axons when expressed alone in neurons [4] or with LKB1 in neural progenitors [5]. Here, we quantified the proportion of green fluorescent
protein positive (GFP+ ) cells with one or more axons after overexpression of each STRAD splice form with or without LKB1. We found that
when LKB1 or each STRAD isoform was individually expressed with GFP-expressing control vector, no significant increases in axon number per
neuron were observed (Figure?2A-G,H), consistent with prior observations [5].When paired with LKB1, we found that all tested STRAD? splice
forms are capable of eliciting multiple axons in a significant proportion of neurons, compared with the STRAD isoform?+?GFP-expressing vector
(Figure?2B,B?-E?). In contrast, only the full-length form of STRAD? was able to induce a similar phenotype (Figure?2F?,G?) while STRAD?-2
does not significantly affect axogenesis (Figure?2G,G?).
Figure 2: Over-expression of STRAD isoforms leads to the initiation of multiple axons. Multiple splice variants of each STRAD gene were
tested for their ability to elicit supernumerary axons alone or with LKB1. Wild-type E15.5 cortices were electroporated with designated constructs
and axon number, as determined by MAP2/Tau immuno-labeling, was quantified in GFP+ cortical neurons after five days in vitro. Representative
neurons from each condition are shown. Neither LKB1 nor individual STRAD? splice forms exhibit a significant increase in multi-axon cells (A-
G) . When co-expressed with LKB1, all forms of STRAD are sufficient to significantly drive the formation of multiple axons (B?-F?) except the
truncated form of STRAD?, (G, G?) . Scale bar?=?50??m. ***P <0 .001 (two-way ANOVA with Bonferroni?s post-test comparing the STRAD
isoform?+?LKB1 with the STRAD isoform?+?GFP). (H) Quantification of N?=?3 to 6 independent experiments for each set of constructs. >300
GFP+ cells counted in each condition. ANOVA, analysis of variance; E, embryonic day; MAP2, microtubule associated protein 2. [see PDF for
image]
Genetic elimination of both STRAD genes in the cerebral cortex disrupts the formation of projection axons
To address the in vivo complementation of the STRAD paralogs, we generated two novel mouse lines (a STRAD?-null line and a conditional allele
of STRAD? (see Additional file 1: Figure S3A)). The STRAD? constitutive null animals do not produce STRAD? protein (see Additional file 1:
Figure S3B) and expire perinatally (see Additional file 1: Figure S3C), while the STRAD? null mice have no overt phenotypes. Histologic
characterization of cerebral cortices indicated that elimination of either STRAD? (Figure?3B,B?) or STRAD? (Figure?3C,C?) alone is not
sufficient to disrupt axogenesis. However, deletion of both STRAD genes caused a profound loss of TAG1-positive projection axons (Figure?3D,
D?), mirroring the effect observed following conditional deletion of LKB1 [5]. Similarly, neuronal polarization defects (indeterminate neurites)
were observed in primary cortical cultures of STRAD?/? double KO cortices compared to controls when immuno-stained for the axon/dendrite
markers Tau1 and microtubule associated protein 2 (MAP2), respectively (see Additional file 1: Figure S3E-G). This indicates that either STRAD?
or ? is sufficient to drive axogenesis during corticogenesis.
Figure 3: STRAD? and STRAD? are redundant in axogenesis and limiting programmed cell death. Embryonic day 18.5 coronal sections
immunolabeled for either corticofugal fibers (Tag1, green) (A-D, A?-D?) or activated caspase3 (Act-Casp3, green) (E-H, E?-H?) and a nuclear
marker (DRAQ5, magenta in A -D , blue in E -H ). Axons are normal in wild-type, STRAD? KO and STRAD? cKO brains, but completely gone
in the STRAD?/STRAD? double KO brain (A-D) . Scale bar?=?100??m. Activated caspase3 is largely absent from wild-type, STRAD? KO and
STRAD? cKO brain, but drastically increased in STRAD?/? double KO cortex (E-H, E?-H?) . Scale bar?=?100??m. Higher magnifications of
cortical regions of TAG1 immunolabeling and activated caspase 3 are shown in grayscale to the right (A?-D? and E?-H?) . [see PDF for image]
Deletion of both STRAD paralogs results in programmed cell death in the cerebral cortex
To test whether eliminating either or both STRAD genes parallels the cortical loss of LKB1 in the context of programmed cell death, we examined
activated caspase3 in cortical tissue. Immuno-staining of either the single STRAD? KO (Figure?3E,E?) or STRAD? cKO (Figure?3F,F?) cortices
indicates no change in apoptosis relative to wild-type control (Figure?3G,G?). In contrast, the STRAD?/? double KO cortex displays substantial
activated caspase3 immuno-labeling, an obvious thinning of the cortical wall, and enlarged ventricles (Figure?3H,H?), a phenotype also observed
in the LKB1 cKO mice [5]. These results indicate that loss of both STRAD? and STRAD? is required to phenocopy loss of LKB1, demonstrating
the functional redundancy between these LKB1-activating pseudokinases, and establishing the sufficiency of STRAD? in corticogenesis.
Loss of STRAD?, but not STRAD?, reduces LKB1 stability in vivo
Given the similarity with LKB1 phenotypes, we tested whether endogenous LKB1 expression is affected by loss of either or both STRAD proteins
in vivo . We find loss of STRAD? leads to a significant decrease (approximately 85%) in LKB1 protein levels in the embryonic (embryonic day
(E16.5) cerebral cortex (Figure?4A-B), a result mirrored in other tissues (see Additional file 1: Figure S4B). This observation is despite a
significant increase in LKB1 transcription (see Additional file 1: Figure S4A), indicating that regulation of protein expression occurs
predominantly post-transcriptionally. Surprisingly, this reduction in LKB1 levels impairs neither axogenesis nor cell survival (Figure?3).
Figure 4: STRAD?, but not STRAD? stabilizes LKB1 protein. (A) Representative Western blot of lysates from wild-type, STRAD? KO,
STRAD? cKO, or STRAD?/? double KO embryonic day 16.5 (E16.5) cortex. Actin is a loading control. (B) Quantification of LKB1 protein
levels analyzed by Western blot, normalized to wild-type cortical lysate. N ?15 cortices from at least three litters of each genotype. There is no
significant difference between columns 1 and 3 or columns 2 and 4. ***P <0.0001 using one-way ANOVA with Bonferroni?s multiple
comparison test. (C) Western blot of Nestin-cre+ ; STRAD?f+ or STRAD?ff lysates across developmental time. Quantification of LKB1 protein,
normalized to postnatal day 0 (P0) STRAD?f+ ; Nestin-cre+ . N ?3 brains of each genotype from three litters for each time-point. (D) Western blot
of E16.5 cortical lysates showing STRAD? protein is significantly reduced following conditional cortical loss of LKB1. (E and F) Quantification
of N ?4 independent LKB1 stability time-courses in HEK cells transfected with epitope-tagged LKB1 protein following cycloheximide-mediated
translation inhibition, with three to six replicates of each condition in each experiment. (E) STRAD?-2 significantly increases LKB1 half-life, as
does STRAD?-1, to a lesser extent. (F) LKB1?NLS is as stable as LKB1?+?STRAD?-2 and LKB1?NLS?+?STRAD?-2 is similar to
LKB1?NLS?+?Vector. Error bars represent SEM. Repeated measures ANOVA with Dunnett?s multiple comparison test with LKB1?+?empty
vector as the control was employed. ***P <0.001, **P <0.005. ANOVA, analysis of variance; KO, knockout; SEM, standard error of the mean.
[see PDF for image]
In contrast, STRAD? deletion does not affect LKB1 levels, nor is the effect exacerbated by loss of both pseudokinases (Figure?4A-B). We
observe a reciprocal in vivo stabilizing relationship between LKB1 and STRAD?, as cortical lysates from LKB1fl/fl : Emx1-cre mice display a
significant reduction in STRAD? levels (Figure?4D), extending observations of STRAD? and LKB1 stability we and others have previously made
in vitro [4, 26, 27, 28, 29, 30]. A developmental analysis using a conditional allele of STRAD? (see Additional file 1: Figure S3A,D) indicates that
cortical LKB1 expression is compromised by STRAD? loss in all post-natal ages examined (Figure?4C), indicating that STRAD? is absolutely
required to achieve normal levels of LKB1. The fact that this dramatic reduction in LKB1 levels in the STRAD? KO did not affect axon formation
led us to explore how this alteration in protein expression impacts LKB1 phosphorylation at serine 428 (S431 in murine LKB1), a post-
translational modification of LKB1 that we and Shelley et al. have shown to be critical for axogenesis [4, 5]. Western blot analysis indicates that
the proportion of LKB1 phosphorylated on S431 increases relative to total LKB1 in the STRAD? KO, but that the total amount of pS431 is
essentially unchanged (see Additional file 1: Figure S4E).
We find that HEK293 cells exhibit similar patterns of STRAD-dependent LKB1 stability (Figure?4E, see Additional file 1: Figure S4F), as
observed in prior studies [4, 29]. In these cells, we were able to replicate the stabilizing effects of STRAD? on LKB1 by measuring protein
turnover following cycloheximide-mediated protein synthesis inhibition (Figure?4E-F). These results show that STRAD? co-expression can
preserve LKB1 protein levels, but to a lesser extent than STRAD?. This observation likely represents sequestration of LKB1 in the cytoplasm by
the predominantly cytoplasmic STRAD?. Using a previously validated LKB1-interaction mutant of STRAD?-2 (YHF, Y185F/H231A/F233A) [9,
31], we find that LKB1-binding by STRAD? is required for this stabilizing effect (Figure?4E, see Additional file 1: Figure S4F), indicating that
direct interaction mediates the stabilization of LKB1.
Previous biochemical and cell biological studies have specifically implicated STRAD? in shuttling LKB1 to the cytoplasm [6, 32], as STRAD?
lacks key residues involved in the interaction with the nuclear export machinery [32]. We tested whether the nuclear export function of STRAD?
could be contributing to LKB1 stability by altering LKB1 sub-cellular localization, potentially sequestering the kinase from degradation. To do
this, we examined LKB1 stability in the context of a nuclear-localization signal (NLS) mutant of LKB1 (LKB1-?NLS) [33] (Figure?4F, see
Additional file 1: Figure S5). LKB1-?NLS demonstrates a robust stabilization when expressed alone (Figure?4F), and this increased stability is not
significantly different from WT-LKB1 expressed in combination with STRAD?-2, nor is the stability of LKB1-?NLS further enhanced by co-
expression of STRAD?-2 (Figure?4F). Given that nuclear export of LKB1 affects its stability and that splice forms of STRAD? can contain an
additional nuclear export signal (NES), we tested how these isoforms (STRAD?-1 and ?7) impact STRAD?s ability to stabilize LKB1 and did not
observe any significant differences in LKB1 stability conferred to these STRAD? splice variants (see Additional file 1: Figure S4G).
Discussion
The integral relationship between these two pseudokinases and their partner kinase is evidenced by the fact that all species bearing an LKB1 locus
also contain at least one STRAD gene. Here, we provide evidence that STRAD? is likely the phylogenetic ancestor of the STRAD paralogs in
vertebrates, with the STRAD duplication event potentially providing selective advantage via genomic redundancy for this protein family.
Our data reveal a complex expression pattern of STRAD proteins in both developing and adult tissues and identify a new form of STRAD?
(STRAD?-7) not previously reported. We also establish that the STRAD?-1 splice form is restricted to brain, skeletal muscle and testis in the
mouse. Most intriguing is our discovery that a second nuclear export sequence within the amino-terminus STRAD? that has been previously
demonstrated to be functional for LKB1 export [32] is developmentally regulated by splicing during brain development. While the STRAD?
carboxy-terminal export signal contains a phosphorylation site targeted by LKB1 [7], this N-terminal NES lacks any known post-translational
modification, and may represent a less regulated form of STRAD? nuclear export.
Our work and that of others demonstrates LKB1 to be a requisite component of the transduction machinery underlying axon formation [4, 5] and
other cell polarity hallmarks [10, 34]. Acute knockdown of STRAD? with small hairpin RNAs (shRNAs) leads to dysregulated mTOR signaling in
the CNS [35, 36], supporting the idea that STRAD? is also an important regulator of nervous system function. Biochemical characterization of the
LKB1: STRAD complex indicates that its formation is required for allosteric activation of LKB1 [7, 22, 31]. Previous neuronal loss-of-function
studies have not distinguished between a requirement of LKB1 protein expression and kinase activity, but our in vivo data demonstrate that
without these critical activator proteins, LKB1 is unable to elicit axon specification (Figure?3). We demonstrate that either STRAD protein is
competent to drive axogenesis, and report the first in vivo physiological contribution of STRAD?.
It is important to note that previous studies evaluating STRAD? function biochemically and cell biologically have often used the STRAD?-1 form.
Our results indicate that additional studies may be required to clarify the cellular context and specific roles of STRAD? depending on which
isoforms of the protein are normally expressed in a given cell type or tissue. It is possible that these amino-terminal variants of STRAD? may
affect recruitment of additional components to STRAD: LKB1 signaling complexes or result in alteration in localization or allosteric activation of
LKB1, as previously suggested [23].
Furthermore, the increased apoptosis we observe following simultaneous inactivation of both STRAD genes provides another parallel with the
LKB1 cKO [5] and suggests that allosteric activation of LKB1 plays a significant role in cell survival. This apoptosis likely results from failed
axogenesis and subsequent loss of trophic support [5, 17] as indicated by studies using conditional LKB1 mice and the post-mitotic cre
recombinase regulated by the NEX (NeuroD6/MATH2) promoter. Whether compromised axogenesis is the sole driver triggering this cell death
remains unclear, but it is possible that additional survival pathways have also been affected by LKB1 or STRAD?/? loss. Future studies exploring
the nature and extent of this cell death, as well as the timing of its induction relative to when cortical axons encounter their intermediate and final
targets should be of great value.
Our results also indicate that STRAD? uniquely plays a significant role in stabilizing LKB1 protein levels in vivo and that this stabilizing effect
arises in large part from the binding and sub-cellular localization conferred upon LKB1 by STRAD?. This is consistent with a previous study
mapping the STRAD-MO25 interaction using carboxy-terminal deletions of STRAD? [6]; however, this study did not directly implicate the
deleted carboxy-terminal NES. Interestingly, the ability to stabilize LKB1 is not potentiated by STRAD? isoforms containing an additional NES,
leaving open the role of the splicing-regulated amino terminal export signal. The nuclear localization of LKB1 also appears to be a vertebrate
specialization, as invertebrate forms of LKB1 have been shown to localize to the cytoplasm and plasma membrane [37, 38] while mammalian
LKB1 consistently displays a partially nuclear component (see Additional file 1: Figure S5, [32, 39]. This is the first report of regulated LKB1 and
STRAD? stability in vivo, expanding upon previous work in cultured cells [4, 26, 27, 28, 29, 30] . The third component of the LKB1: STRAD
complex, MO25, is not affected by the loss of either protein (see Additional file 1: Figure S4C), an interesting result given previous work
demonstrating that shRNA-mediated MO25 knockdown led to a reduction in LKB1 protein levels [6]. It has recently been shown that MO25 is
also a critical component in regulating the Mst and OSR1/SPAK family of kinases [22] and, thus, may be stabilized through interaction with these
or other partner proteins, or may not be under the same regulatory mechanism targeting STRAD? or LKB1.
Efforts to understand LKB1 stability have revealed roles for heat shock proteins 70 and 90 (HSP70 and HSP90), as well as the proteasome in
targeting STRAD? for degradation and indicate that STRAD? and HSP90 exist as competitors for LKB1 binding [26, 40, 41, 42]. Here we show
for the first time that a reciprocal relationship exists between STRAD? and LKB1 in vivo such that LKB1 loss leads to a reduction in STRAD?
protein levels (Figure?4D, see Additional file 1: Figure S4D). Our observation of reciprocal stability is similar to that seen for other protein-
binding partner pairs such as TSC1/2 [43] and Mdm2/SHP [44]. While it is unclear whether similar strategies exist for proteasomal avoidance in
various protein pairs, this coordinated protein regulation between related and requisite components of a given signaling pathway likely represents
an additional layer of coordinate regulation.
The failure of STRAD? to compensate in vivo for the loss of STRAD? (Figure?4A,B) highlights the primal role of STRAD?. While axon
formation is not affected by STRAD? deletion, additional functions within particular cell types and tissue requiring greater amounts of LKB1 may
be compromised. Since PMSE patients exhibit symptoms linked to specific organ systems [8], this may reflect the lack of redundancy in LKB1
stabilization between STRAD? and ?. The fact that human patients often survive into early adolescence while STRAD? KO mice die perinatally
may also indicate additional functions or alternate developmental expression patterns for human STRAD? compared to mouse STRAD?.
Pseudokinases have been proposed to occupy approximately 10% of the human kinome [45] but in many cases the function of these proteins
remains obscure. Our efforts assign both redundant and unique functions to two of these pseudokinases. The specific and profound nature of the
effects caused by perturbing the LKB1: STRAD dyad leads to the conclusion that, as a crucial regulator of multiple signaling pathways, LKB1
signaling requires such redundancy in its activation scheme. Our evolutionary-based results illuminate a clear and meaningful phylogenetic
relationship between these evolutionarily conserved pseudokinases consistent with our previous LKB1 loss of function studies. STRAD? emerges
as the clear primal paralog and these results present a new context in which to understand parallels between invertebrate and vertebrate functions
of STRAD proteins. This analysis sets the groundwork to extend our understanding of how STRAD proteins have expanded functionalities across
evolutionary time while displaying paralog-restricted specializations in vertebrate organisms. These results also demonstrate the necessary role of
these proteins in the developing nervous system and add STRADs to the collection of proteins required for axogenesis.
Conclusions
LKB1 is an important regulator of neuronal polarity and axogenesis, yet its nuanced regulation by the STRAD proteins had remained largely
unexplored. Here we provide evidence of the evolutionary primacy of STRAD?. We also demonstrate that messenger RNAs for the STRAD
paralogs undergo a tremendous amount of tissue-restricted and cell-type specific splicing. We show that either STRAD? or STRAD? is necessary
and sufficient for axon formation in the developing cortex, the first report of such functional redundancy between STRAD? and STRAD?
(Figure?5). Most importantly, we find that only STRAD? can significantly stabilize LKB1 protein in vivo and that this stabilizing effect is required
for up-regulation of LKB1 expression during brain development and maturation. LKB1 stabilizes STRAD? in vivo as well, indicating a reciprocal
stabilizing relationship between this kinase and its regulatory partner. The normal axogenesis we observe in the absence of STRAD? indicates that
low levels of LKB1 are sufficient to provide the necessary signaling to permit axon specification in the developing cortex. In contrast, the perinatal
lethality of these STRAD?-null mice indicates a stronger sensitivity to LKB1 expression levels in other organ systems. Taken together, our data
establish a previously unknown redundancy for STRAD? in axogenesis and demonstrate a unique role for STRAD? in stabilizing LKB1 protein
(Figure?5).
Figure 5: Schematic summarizing the activation and turnover of LKB1 in a polarizing neuron as it transits along a radial glial fiber.
STRAD? shuttles from the cytoplasm to the nucleus (1). At least two possible outcomes exist for nuclear LKB1 either binding to STRAD? (2) or
degradation via the proteasome (3). Once exported by STRAD? to the cytoplasm, LKB1 can drive axogenesis (4) by either remaining bound to
STRAD? or by binding STRAD?. In the latter case, STRAD? may return to the nucleus once again (5). [see PDF for image]
Methods
Phylogenetic analysis
Sequences were aligned using multiple sequence comparison by log-expectation (MUSCLE). Phylogenetic analysis was performed using MPI
version of MrBayes 3.1.2 with MPICH2 installed by running in parallel on eight nodes [46, 47]. Bayesian trees with posterior probabilities were
constructed with mixed amino acid models, a gamma distribution for rate variation among sites and a proportion of invariable sites. MrBayes was
executed with two runs (four chains for each run), four million generations of Markov Chain Monte Carlo (MCMC) analyses, with 1,000 as the
sample frequency and with a temperature parameter 0.2. The number of MCMC generations assured convergence of the two runs by having a
standard deviation of split frequencies less than 0.005. The posterior probability of each split was estimated by sumt with 1,000 trees discarded as
burnin based on the plot of ?generation vs. log probability?. Tree with branch lengths and posterior probabilities is shown in Additional file 1:
Figure S1. Parameters were summarized by sump with 1,000 burnin, and values for the Potential Scale Reduction Factor (PSRF) were all close to
1.0 for all parameters. Scale bar represents amino acid replacements/site/unit evolutionary time.
Animals
All mouse experiments in this study were performed using methods and protocols reviewed and approved by the Oregon Health and Science
University Institutional Animal Care and Use Committee (protocol number IS00001565) or the Utrecht University Institutional Animal Care and
Use Committee (protocol number HL05.1010 and governmental approval number E17) and were carried out in accordance with National Institutes
of Health standards and following established guidelines of the Public Health Service. The STRAD? gene trap mice were generated by random
insertion of a virally-encoded splice acceptor cassette into mouse embryonic stem cells (Lexicon Genetics, see Additional file 1: Figure S3A) and
STRAD?-floxed transgenics bear Cre recombinase recognition sites flanking exon 2 which encodes the start codon of the open reading frame (see
Additional file 1: Figure S3A). For conditional and germ-line deletion, the STRAD? conditional line was mated to mice carry cre recombinase
under the control of either the empty spiracles homeobox 1 (Emx1) or cytomegalovirus (CMV) promoter. LKB1 floxed mice are available from
the National Cancer Institute Mouse Repository (strain number 01XN2) .
Constructs and reagents
Total RNA from mouse tissues was extracted using Trizol reagent (Life Technologies, Grand Island, NY, USA) alone or in combination with
RNeasy Mini Kit (Qiagen, Valencia, CA, USA). A total of 2??g RNA was used as a template with Superscript VILO cDNA Synthesis Kit (Life
Technologies). Alternatively, we employed a polyadenylated mRNA-derived cDNA tissue panel (Clontech, Mountain View, CA, USA). Splice
forms of STRAD? were amplified using Taq polymerase (Qiagen) with the following primers of the STRAD? message in mouse. The sequences
for 5? segments were as follows: 5?-TGCGCTCTGACTCCTAGACC-3? and 5?-GCTGCTCATCATCTCTGGTTT-3?. To detect 3? splicing,
primers targeting this region were: 5?-TACGGCTCTGCAAGGATCT-3? and 5?-AGTTGGTGATGGGAGTGACTG-3?.
STRAD? was amplified using the following primers:
5?-TCTGCACCAAAATGGCTGTA-3? and 5?-ACATCCAGTGGGCTATACGG-3?. Amplicons were purified and sub-cloned into either the
TOPO-TA pCR 2.1 or pCR Blunt vector (Life Technologies) and sequenced using M13 forward or reverse primer. Quantitative RT-PCR was
carried out based on the manufacturers protocol (Applied Biosystems ? Life Technologies, Grand Island, NY) using total RNA extracted as
described above.
Ex utero electroporation and primary neuron culture
Ex utero electroporation was performed as described previously using a 2??g/?L final concentration of cDNA in STRAD/LKB1 overexpression
experiments (5). After electroporation, cortices were dissected, dissociated and plated on poly-D-Lysine-laminin coated coverslips (BD
Biosciences, San Jose, CA, USA), cultured for multiple days in vitro in Neurobasal media supplemented with B27 supplement, penicillin-
streptomycin, and Glutamax (all from Life Technologies).
Astrocyte culture
Astrocytes were cultured according to the Banker method from P1 pups [48]. They were fed every third day with glial MEM (MEM, 20% glucose,
penicillin/streptomycin, 10% heat-inactivated horse serum) ? all from Life Technologies. RNA was collected once astrocytes reached confluency.
Immunohistochemistry
Cells and tissues were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) for 20?minutes at room temperature (cells) or overnight
at 4?C (tissues) on a rotating shaker. Before immunostaining, they were blocked for one hour in 0.1% cold water fish skin gelatin/1%BSA/0.5%
TritonX-100/0.01?M Tris-buffered saline (TBS) (all from Sigma St. Louis, MO), after which primary antibodies were added (see Additional file 1:
Table S1) overnight at 4?C on a rotating shaker then washed 3 ? 10?minutes in 1x PBS. Alexa-Fluor fluorescent secondary antibodies (Life
Technologies) were applied at 1:1,000 in the same blocking solution with the addition of 5% goat serum for one hour at room temperature in the
dark.
Cycloheximide experiments
Cycloheximide (Sigma) at 100?mg/mL was used at 50??g/mL final concentration in protein stability experiments. All protein stability experiments
were carried out approximately 16?hours after transfection in Optimem media (Life Technologies). For time-courses of LKB1 degradation, cells
were treated at the indicated time point relative to control, then lysed and analyzed by Western blot. The amount of LKB1 protein was normalized
to actin in each sample, and compared with untreated cells from the same experiment to determine the relative amount of LKB1 protein remaining
at each time point. Curves were determined by Prism5 software?s nonlinear fit of exponential decay function.
Abbreviations
BSA: bovine serum albumin; CHX: cycloheximide; CMV: cytomegalovirus; CNS: central nervous system; E: embryonic day; EMX1: empty
spiracles homeobox 1; GFP: green fluorescent protein; HSP: heat shock protein; LKB1: liver kinase B1; MAP2: microtubule associated protein 2;
MO25: mouse protein 25; NEX: (NeuroD6/MATH2); NES: nuclear export signal; NLS: nuclear-localization signal; P: postnatal day; PBS:
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